Description

The OMNIPOD 5 Automated Insulin Delivery System offers a comprehensive solution for individuals managing type 1 and type 2 diabetes. Designed for users aged 2 years and older, this system provides a seamless, tubeless, and waterproof insulin delivery method, enhancing convenience and discretion.

Key Components

• Pod: The wearable Pod delivers insulin continuously for up to three days. It features automatic cannula insertion and a reservoir capacity accommodating 85 to 200 units of U-100 rapid-acting insulin. Its compact size and lightweight design make it discreet and easy to wear.

• Controller/App: Users can manage the system via the Omnipod 5 App on compatible smartphones or an Insulet-provided Controller. The app and Controller communicate with the Pod through Bluetooth, offering intuitive navigation and remote software updates.

Advanced Integration

The system integrates with leading Continuous Glucose Monitors (CGMs) such as Dexcom G6, Dexcom G7, and FreeStyle Libre 2 Plus. This integration enables the OMNIPOD 5 to adjust insulin delivery automatically, using SmartAdjust™ technology to maintain glucose levels within customizable targets.

Features

• Automated Insulin Delivery: The closed-loop system adjusts insulin every five minutes based on CGM data, reducing the need for fingersticks and enhancing glucose management.

• SmartBolus Calculator: This feature suggests bolus doses tailored to individual needs, considering factors like carbohydrate intake and current glucose levels.

• Activity Settings: Users can modify insulin delivery during exercise or periods of increased hypoglycemia risk, providing flexibility and safety.

Compatibility

The system supports various Android and iPhone models, ensuring broad accessibility. It operates securely with encrypted communication and does not require continuous internet access, allowing functionality even in airplane mode.

User Experience

The OMNIPOD 5 is designed for ease of use, with no calibration required and support for both English and Spanish. It enhances user experience with features like discreet design, robust data management, and seamless integration into daily life.

Safety and Guidelines

A prescription is required, and initial setup should be conducted with a healthcare provider. The system is not recommended for certain individuals, such as those unable to monitor glucose effectively or those taking specific medications like hydroxyurea.

Clinical Benefits

Clinical studies indicate significant improvements in HbA1c levels and time spent in target glucose ranges. Users transitioning from other therapies report enhanced psychosocial outcomes, making the OMNIPOD 5 a valuable tool in diabetes management.

With regulatory approvals in the U.S. and Australia, the OMNIPOD 5 Automated Insulin Delivery System stands as a trusted and innovative option for effective diabetes care.